From an oncological perspective, as BRCA1/2 protein defects sensitize breast tumor cells to various chemotherapeutic agents that induce DNA lesions [17, 24, 25], we investigated whether there was an association between tumor response to NAC and changes in AMH concentrations during NAC in breast cancer patients. This evidence concerns the gene BRCA1 and breast neoplasm.